Hypertension, heart rate, use of antihypertensives, and incident prostate cancer

Annals of Epidemiology

Volumn 11, Issue 8, 2001, Pages 534-542

  Fitzpatrick, Annette L ^a   Daling, Janet R ^a   Furberg, Curt D ^b   Kronmal, Richard A ^a   Weissfeld, Joel L ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

ACE Inhibitors; Antihypertensives; Beta Blockers; Calcium Channel Blockers; Diuretics; Heart Rate; Hypertension; Prostate Cancer; Vasodilators

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGED; ARTICLE; CANCER GROWTH; CLINICAL EXAMINATION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG USE; FOLLOW UP; HEART RATE; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REGRESSION ANALYSIS; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 0035166782     PISSN: 10472797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-2797(01)00246-0     Document Type: Article

References (53)

1. Prostate cancer
2. Prostatic cancer: An age-old problem
3. Risk factors for prostate cancer
4. Prostate cancer: A current perspective
5. High blood pressure: A risk factor for cancer mortality?
6. High blood pressure and cancer?
7. Mortality and morbidity during 13.5 years follow-up in relation to blood pressure
8. High blood pressure and 17-year cancer mortality in the Western Electric Health Study
9. Heart rate and prostate cancer mortality: Results of a prospective analysis
10. Blood pressure and heart rate: No evidence for a positive association with prostate cancer
11. Positive association between resting heart rate and cancer incidence in current and former smokers
12. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure
13. Population awareness and control of hypertension and hypercholesterolemia. The Atherosclerosis Risk in Communities Study
14. Elderly hypertensive patients: Are they adequately treated?
15. The Cardiovascular Health Study: Design and rationale
16. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study
17. Assessing the use of medications in the elderly: Methods and initial experience in the Cardiovascular Health Study
18. Picture sort method for administering a food frequency questionnaire to older adults
19. Surveillance and ascertainment of cardiovascular events: The Cardiovascular Health Study
20. Cancer and hypertension: An unresolved issue
21. Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies
22. Heart rate: A risk factor for cancer?
23. Heart rate, physical activity and mortality from cancer and other noncardiovascular diseases
24. Calcium channel blockade and incidence of cancer in aged populations
25. Calcium-channel blockers and risk of cancer
26. Cancer risk in users of calcium channel blockers
27. Cancer risk of hypertensive patients taking calcium antagonists
28. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
29. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?
30. Calcium channel blocker use and the risk of prostate cancer
31. Sex influence on renal alpha 2-adrenergic receptor density in the spontaneously hypertensive rat
32. Castration lowers and testosterone restores blood pressure in several rat strains on high sodium diets
33. Possible involvement of androgen in increased norepinephrine synthesis in blood vessels of spontaneously hypertensive rats
34. Androgenic effects of oral contraceptives: Implications for patient compliance
35. Androgen excess in women
36. Does long-term blood pressure reduction in patients with essential hypertension improve concomitant metabolic disorders?
37. Relative androgenicity, blood pressure levels, and cardiovascular risk factors in young healthy women
38. Estrogen replacement therapy and cardiovascular protection: Lipid mechanisms are the tip of an iceberg
39. Cardiovascular protection by oestrogen - A calcium antagonist effect?
40. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women
41. Prospective study of sex hormone levels and risk of prostate cancer
42. Zinc, copper and selenium in reproduction
43. State of the hypophyseal-gonadal system in patients with hypertension during long-term treatment with nadolol and anaprilin
44. Effects of verapamil on diurnal and thyrotropin-releasing hormone-stimulated prolactin levels in man
45. Calcium and prolactin secretion in humans: Effects of the calcium channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia
46. Gynecomastia
47. Gynecomastia associated with calcium channel blocker therapy
48. Unilateral gynecomastia induced by treatment with diltiazem
49. Gynecomastia in association with calcium antagonists
50. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women